Gene Therapy Ready Site Network
Advarra is registered with the NIH as the IBC of record for 1,200+ research sites that are vetted and prepared to conduct your next clinical trial.
Join the Gene Therapy Network
Leverage the world’s largest integrated IRB and IBC service combined with the most comprehensive Gene Therapy Ready site network to move your clinical trials forward—faster.
Gene Therapy Ready Sites:
Receive complimentary registration with the NIH when Advarra serves as your IBC of record
Demonstrate expertise and readiness to conduct your trials involving genetically engineered therapies and vaccines
Complete study startup 5-6 weeks faster than non-GTR sites and 8-12 weeks faster than sites using a local IBC
Is Your Site Ready?
Research into gene therapy-based treatments and mRNA-based vaccines is accelerating exponentially. Is your research site ready to take advantage of this growing area of clinical trials?
Become Gene Therapy Ready by using Advarra as your registered IBC!
Request a Complete List of Gene Therapy Ready Sites
Finding sites ready to perform gene therapy and mRNA-based drug and vaccine trials just got easier.
Turnaround Time
Turnaround can depend on a site’s experience with and preparation for IBC review. Sites in Advarra’s Gene Therapy Ready network have an existing IBC and prior experience with human gene transfer studies. When Advarra is selected as the central IRB and IBC, these sites are often reviewed and approved for a new gene therapy and mRNA vaccine research study in just a few days.
